ST Pharm will join the ranks of COVID-19 vaccine development. It introduced mRNA vaccine platforms such as Pfizer and Moderna vaccines.

ST Pharm announced on the 24th that it has applied for a phase 1 clinical trial plan for the mRNA-based COVID-19 prevention vaccine STP-2104 to the MFDS.

Clinical trials were planned in stages of capacity increase, multisystem, and disclosure to evaluate the safety and immunogenicity of the COVID-19 vaccine STP-2104 for healthy adults aged 19 to 55. The clinical scale is at least 30, and the subjects will be divided into two groups, and STP2104 will be administered twice with doses of 25㎍ and 50㎍, respectively, to confirm safety and immunogenicity. Acco